RPS launches new project to tackle medicines shortages

The Royal Pharmaceutical Society (RPS) has announced that it will head up a new medicine shortages advisory group due to meet “later this month”. 

“We look forward to bringing together experts...to examine what steps can begin to make a difference"

The membership body’s “new project” will “examine the causes” and “help tackle” the impact of medicines shortages, it has said.

The RPS yesterday (March 13) announced that the advisory group, which will meet “later this month”, will be chaired by RPS Fellow and former deputy Chief Pharmaceutical Officer (CPhO) Dr Bruce Warner.

Convened by the RPS, the group will also include “experts from primary and secondary care, patients, the pharmaceutical industry, suppliers, regulators, government and the NHS”, it said. 

Read more: HSCC: ‘Nonsensical’ that pharmacists lack generic substitution powers

It added that the group will “develop a report” to support “debate on UK policy” and “provide expert thought leadership”, with recommendations “to address the factors behind medicine shortages and steps to take to reduce their impact”.

Its work will be informed by “a literature review, stakeholder interviews, online RPS member events and patient stories”, it said.

“Practical, short-term solutions”

Commenting on the launch, RPS president Professor Claire Anderson said the group will “bring together key stakeholders, undertake research and offer solutions”.

She stressed that “helping patients get the medicines they need is at the very core of pharmacy practice”.

Read more: Pharmacists altering prescriptions could ‘exacerbate’ shortages, says minister

Health charity coalition National Voices director of policy and external affairs Sharon Brennan said that its members “are increasingly hearing from the people they advocate for regarding concerns around medicine shortages”.

“We are hopeful this advisory group will consider practical, short-term solutions to the current problems patients are facing alongside longer-term solutions,” she added.

Read more:Asthma drug under ‘review’ after surge in psychiatric incidents

And Dr Warner said that the RPS looks forward to examining “what steps can begin to make a difference for patients”.

Last month, chair of the health and social care committee (HSCC) Steve Brine told the 2024 Sigma conference that medicines shortages threaten to “undermine” the government’s goal for Pharmacy First.

He said that it was “nonsensical” that pharmacists lack the “autonomy” to supply a different type of the same medication when confronted with shortages.

Sign in or register for free

Kate Bowie

Read more by Kate Bowie

Kate Bowie joined C+D as a digital reporter in August 2023 after graduating from a master’s in journalism at City, University of London. She began covering the primary care beat at the end of 2022, when she carried out several health investigations focused on staffing issues, NHS funding and health inequalities.

Latest from News

Retired pharmacist crushed to death in canal boat accident

 
• By 
 • comment

Margaret Billings sustained fatal injuries when she was caught between a moving boat and a riverbank during a day out “with family and friends”, an inquest has found.

NHSE scrapped: ‘Fresh start or just more political chaos?’

 
• By 
 • comment

C+D rounds up some of the immediate pharmacy reaction to news that NHS England will be abolished, with more control moving back to the government and local leaders…

New primary care medical director role as 2-year NHSE axing begins

 
• By 
 • comment

Wes Streeting has revealed that the DH is “immediately” working to scrap NHS England (NHSE) and put a new “transformation team” in place – adding that it is in the “very final stages” of concluding a new pharmacy contract deal.

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.